Advertisement

Drugs & Aging

, Volume 19, Issue 3, pp 179–202 | Cite as

Strategy for the Management of Vasovagal Syncope

Therapy in Practice

Abstract

The disorders of autonomic control associated with orthostatic intolerance are a diverse group of syndromes that can result in syncope and near-syncope. A basic understanding of the pathophysiology of these disorders is essential to diagnosis and proper treatment. It is especially important to recognise the difference between the effect of prolonged upright posture on a failing autonomic nervous system (a hyposensitive or dysautonomic response) and the vasovagal response (which may be a hypersensitive response). Vasovagal syncope is the most common abnormal response to upright posture and occurs in all age groups. The advent of tilt table testing has helped define a population with an objective finding during provocative testing that has enabled researchers to study the mechanism of vasovagal syncope and to evaluate the efficacy of treatments. In most patients, vasovagal syncope occurs infrequently and only under exceptional circumstances and treatment is not needed. Treatment may be indicated in patients with recurrent syncope or with syncope that has been associated with physical injury or potential occupational hazard. Based on study data, patients with vasovagal syncope can now be risk stratified into a high-risk group likely to have recurrent syncope and a low-risk group.

Many patients with vasovagal syncope can be effectively treated with education, reassurance and a simple increase in dietary salt and fluid intake. In others, treatment involves removal or avoidance of agents that predispose to hypotension or dehydration. However, when these measures fail to prevent the recurrence of symptoms, pharmacological therapy is usually recommended. Although many pharmacological agents have been proposed and/or demonstrated to be effective based on nonrandomised clinical trials, there is a remarkable absence of data from large prospective clinical trials. Data from randomised placebo-controlled studies support the efficacy of β-blockers, midodrine, serotonin reuptake inhibitors and ACE inhibitors. There is also considerable clinical experience and a consensus suggesting that fludrocortisone is effective. Encouraging new data suggest that a programme involving tilt training can effectively prevent vasovagal syncope. For patients with recurrent vasovagal syncope that is refractory to these treatments, implantation of a permanent pacemaker with specialised sensing/pacing algorithms appears to be effective. A number of larger clinical trials are underway which should help further define the efficacy of a number of different treatments for vasovagal syncope.

Keywords

Disopyramide Midodrine Fludrocortisone Orthostatic Intolerance Tilt Table 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Grant support: This review was written when the author was supported by HL03466 from the NHLBI of the NIH. Conflict of Interests: The author is a consultant to Shire Pharmaceuticals Inc., which manufactures midodrine HCl.

References

  1. 1.
    Kenny RA, Bayliss J, Ingram A, et al. Head-up tilt: a useful test for investigating unexplained syncope. Lancet 1986; 1: 1352–5PubMedCrossRefGoogle Scholar
  2. 2.
    Ward CR, Gray JC, Gilroy JJ, et al. Midodrine: a role in the management of neurocardiogenic syncope. Heart 1998; 79: 45–9PubMedGoogle Scholar
  3. 3.
    Raviele A, Brignole M, Sutton R, et al. Effect of etilefrine in preventing syncopal recurrence in patients with vasovagal syncope: a double-blind, randomized, placebo-controlled trial. The Vasovagal Syncope International Study. Circulation 1999; 99: 1452–7PubMedCrossRefGoogle Scholar
  4. 4.
    Mahanonda N, Bhuripanyo K, Kangkagate C, et al. Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results. Am Heart J 1995; 130: 1250–3PubMedCrossRefGoogle Scholar
  5. 5.
    Connolly SJ, Sheldon R, Roberts RS, et al. The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol 1999; 33: 16–20PubMedCrossRefGoogle Scholar
  6. 6.
    Di Girolamo E, Di Iorio C, Sabatini P, et al. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999; 33: 1227–30PubMedCrossRefGoogle Scholar
  7. 7.
    Zeng C, Zhu Z, Liu G, et al. Randomized, double-blind, placebo-controlled trial of oral enalapril in patients with neurally mediated syncope. Am Heart J 1998; 136: 852–8PubMedCrossRefGoogle Scholar
  8. 8.
    Bloomfield DM, Sheldon R, Grubb BP, et al. Putting it together: a new treatment algorithm for vasovagal syncope and related disorders. Am J Cardiol 1999; 84(8A): 33Q–9QPubMedCrossRefGoogle Scholar
  9. 9.
    Grubb BP, Karas B. Clinical disorders of the autonomic nervous system associated with orthostatic intolerance: an overview of classification, clinical evaluation, and management. Pacing Clin Electrophysiol 1999; 22: 798–810PubMedCrossRefGoogle Scholar
  10. 10.
    Mosqueda-Garcia R, Furlan R, Tank J, et al. The elusive pathophysiology of neurally mediated syncope. Circulation 2000; 102: 2898–906PubMedCrossRefGoogle Scholar
  11. 11.
    Oberg B, Thoren PN. Increased activity in left ventricular receptors during hemorrhage or occlusion of caval veins in the cat — a possible cause of the vaso-vagal reaction. Acta Physiol Scand 1972; 85: 164–73PubMedCrossRefGoogle Scholar
  12. 12.
    Calkins H. Pharmacologic approaches to therapy for vasovagal syncope. Am J Cardiol 1999; 84(8A): 20A–5QCrossRefGoogle Scholar
  13. 13.
    Sutton R, Petersen ME. The clinical spectrum of neurocardiogenic syncope. J Cardiovasc Electrophysiol 1995; 6: 569–76PubMedCrossRefGoogle Scholar
  14. 14.
    Fitzpatrick AP, Banner NB, Cheng A, et al. Vasovagal reactions may occur after orthotopic heart transplantation. J Am Coll Cardiol 1993; 21: 1132–7PubMedCrossRefGoogle Scholar
  15. 15.
    Rudas L, Pflugfelder PW, Kostuk WJ. Vasodepressor syncope in a cardiac transplant recipient: a case of vagal re-innervation. Can J Cardiol 1992; 8: 403–5PubMedGoogle Scholar
  16. 16.
    Mosqueda-Garcia R, Fernandez-Violante R, Tank J, et al. Yohimbine in neurally mediated syncope. Pathophysiological implications. J Clin Invest 1998; 102: 1824–30PubMedCrossRefGoogle Scholar
  17. 17.
    Grubb BP. Pathophysiology and differential diagnosis of neurocardiogenic syncope. Am J Cardiol 1999; 84(8A): 3Q–9QPubMedCrossRefGoogle Scholar
  18. 18.
    Benditt DG. Neurally mediated syncopal syndromes: pathophysiological concepts and clinical evaluation. Pacing Clin Electrophysiol 1997; 20: 572–84PubMedCrossRefGoogle Scholar
  19. 19.
    Sutton R, Petersen ME. The economics of treating vasovagal syncope. Pacing Clin Electrophysiol 1997; 20: 849–50PubMedCrossRefGoogle Scholar
  20. 20.
    Bloomfield D, Maurer M, Bigger JTJ. Effects of age on outcome of tilt-table testing. Am J Cardiol 1999; 83: 1055–8PubMedCrossRefGoogle Scholar
  21. 21.
    Fitzpatrick AP, Theodorakis G, Vardas P, et al. Methodology of head-up tilt testing in patients with unexplained syncope. J Am Coll Cardiol 1991; 17: 125–30PubMedCrossRefGoogle Scholar
  22. 22.
    Streeten DHP, Anderson GH. Delayed orthostatic intolerance. Arch Intern Med 1992; 152: 1066–72PubMedCrossRefGoogle Scholar
  23. 23.
    Grubb BP. Neurocardiogenic syncope. In: Grubb BP, Olshansky B, editors. Syncope: mechanisms and management. Armonk (NY): Futura Publishing, 1998: 73–166Google Scholar
  24. 24.
    Grubb BP, Kosinski DJ, Boehm K, et al. The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing. Pacing Clin Electrophysiol 1997; 20: 2205–12PubMedCrossRefGoogle Scholar
  25. 25.
    Narkiewicz K, Somers VK. Chronic orthostatic intolerance: part of a spectrum of dysfunction in orthostatic cardiovascular homeostasis? Circulation 1998; 98: 2105–7PubMedCrossRefGoogle Scholar
  26. 26.
    Frohlich ED, Tarazi RC, Dustan HP. Hyperdynamic beta-adrenergic circulatory state. Increased beta-receptor responsiveness. Arch Intern Med 1969; 123: 1–7PubMedCrossRefGoogle Scholar
  27. 27.
    Fouad FM, Tadena-Thome L, Bravo EL, et al. Idiopathic hypovolemia. Ann Intern Med 1986; 104: 298–303PubMedGoogle Scholar
  28. 28.
    Streeten DH, Anderson GHJ, Richardson R, et al. Abnormal orthostatic changes in blood pressure and heart rate in subjects with intact sympathetic nervous function: evidence for excessive venous pooling. J Lab Clin Med 1988; 111: 326–35PubMedGoogle Scholar
  29. 29.
    Low PA, Opfer-Gehrking TL, Textor SC, et al. Comparison of the postural tachycardia syndrome (POTS) with orthostatic hypotension due to autonomic failure. J Auton Nerv Syst 1994; 50: 181–8PubMedCrossRefGoogle Scholar
  30. 30.
    Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology 1993; 43: 132–7PubMedCrossRefGoogle Scholar
  31. 31.
    Sutton R, Petersen M, Brignole M, et al. Proposed classification for tilt induced vasovagal syncope. European Journal of Pacing and Electrophysiology 1992; 3: 180–3Google Scholar
  32. 32.
    Sutton R, Bloomfield DM. Indications, methodology, and classification of results of tilt-table testing. Am J Cardiol 1999; 84(8A): 10Q–19QPubMedCrossRefGoogle Scholar
  33. 33.
    Benditt DG, Ferguson DW, Grubb BP, et al. Tilt table testing for assessing syncope. American College of Cardiology. J Am Coll Cardiol 1996; 28: 263–75PubMedCrossRefGoogle Scholar
  34. 34.
    Fitzpatrick A, Sutton R. Tilting towards a diagnosis in recurrent unexplained syncope. Lancet 1989; 1: 658–60PubMedCrossRefGoogle Scholar
  35. 35.
    Almquist A, Goldenberg IF, Milstein S, et al. Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. N Engl J Med 1989; 320: 346–51PubMedCrossRefGoogle Scholar
  36. 36.
    Benditt DG, Remole S, Bailin S, et al. Tilt table testing for evaluation of neurally-mediated (cardioneurogenic) syncope: rationale and proposed protocols. Pacing Clin Electrophysiol 1991; 14: 1528–37PubMedCrossRefGoogle Scholar
  37. 37.
    Raviele A, Menozzi C, Brignole M, et al. Value of head-up tilt testing potentiated with sublingual nitroglycerin to assess the origin of unexplained syncope. Am J Cardiol 1995; 76: 267–72PubMedCrossRefGoogle Scholar
  38. 38.
    Linzer M, Pontinen M, Gold DT, et al. Impairment of physical and psychosocial function in recurrent syncope. J Clin Epidemiol 1991; 44: 1037–43PubMedCrossRefGoogle Scholar
  39. 39.
    Rose S, Koshman ML, McDonald S, et al. Health-related quality of life in patients with neuromediated syncope [abstract]. Can J Cardiol 1996; 12: 131EGoogle Scholar
  40. 40.
    Sheldon R, Koshman ML, Wilson W, et al. Effect of dual-chamber pacing with automatic rate-drop sensing on recurrent neurally mediated syncope. Am J Cardiol 1998; 81: 158–62PubMedCrossRefGoogle Scholar
  41. 41.
    Grimm W, Degenhardt M, Hoffman J, et al. Syncope recurrence can better be predicted by history than by head-up tilt testing in untreated patients with suspected neurally mediated syncope. Eur Heart J 1997; 18: 1465–9PubMedCrossRefGoogle Scholar
  42. 42.
    Natale A, Geiger MJ, Maglio C, et al. Recurrence of neurocardiogenic syncope without pharmacologic interventions. Am J Cardiol 1996; 77: 1001–3PubMedCrossRefGoogle Scholar
  43. 43.
    Sheldon R, Rose S, Flanagan P, et al. Risk factors for syncope recurrence after a positive tilt-table test in patients with syncope. Circulation 1996; 93: 973–81PubMedCrossRefGoogle Scholar
  44. 44.
    Malik P, Koshman ML, Sheldon R. Timing of first recurrence of syncope predicts syncopal frequency after a positive tilt table test result. J Am Coll Cardiol 1997; 29: 1284–9PubMedCrossRefGoogle Scholar
  45. 45.
    Brignole M, Menozzi C, Gianfranchi L, et al. The clinical and prognostic significance of the asystolic response during the head-up tilt test. Eur J Pacing Electrophysiol 1992; 2: 109–13Google Scholar
  46. 46.
    Davidson E, Fuchs J, Rotenberg Z, et al. Drug-related syncope. Clin Cardiol 1989; 12: 577–80PubMedCrossRefGoogle Scholar
  47. 47.
    Bou-Holaigah I, Rowe PC, Kan J, et al. The relationship between neurally-mediated hypotension and the chronic fatigue syndrome. JAMA 1995; 274: 961–7PubMedCrossRefGoogle Scholar
  48. 48.
    El-Sayed H, Hainsworth R. Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope [see comments]. Heart 1996; 75: 134–40PubMedCrossRefGoogle Scholar
  49. 49.
    Younoszai AK, Franklin WH, Chan DP, et al. Oral fluid therapy. A promising treatment for vasodepressor syncope. Arch Pediatr Adolesc Med 1998; 152: 165–8PubMedGoogle Scholar
  50. 50.
    Scott WA, Pongiglione G, Bromberg BI, et al. Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope. Am J Cardiol 1995; 76: 400–2PubMedCrossRefGoogle Scholar
  51. 51.
    Morillo CA, Leitch JW, Yee R, et al. A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally-mediated syncope induced by head-up tilt. J Am Coll Cardiol 1993; 22: 1843–8PubMedCrossRefGoogle Scholar
  52. 52.
    Lee TM, Su SF, Chen MF, et al. Usefulness of transdermal scopolamine for vasovagal syncope. Am J Cardiol 1996; 78: 480–2PubMedCrossRefGoogle Scholar
  53. 53.
    Biffi M, Boriani G, Sabbatani P, et al. Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine. Heart 1997; 77: 268–72PubMedCrossRefGoogle Scholar
  54. 54.
    Cox MM, Perlman BA, Mayor MR, et al. Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope [see comments]. J Am Coll Cardiol 1995; 26: 1293–8PubMedCrossRefGoogle Scholar
  55. 55.
    Klingenheben T, Kalusche D, Li YG, et al. Changes in plasma epinephrine concentration and in heart rate during head-up tilt testing in patients with neurocardiogenic syncope: correlation with successful therapy with beta-receptor antagonists. J Cardiovasc Electrophysiol 1996; 7: 802–8PubMedCrossRefGoogle Scholar
  56. 56.
    Sra JS, Murthy VS, Jazayeri MR, et al. Use of intravenous esmolol to predict efficacy of oral beta-adrenergic blocker therapy in patients with neurocardiogenic syncope. J Am Coll Cardiol 1992; 19: 402–8PubMedCrossRefGoogle Scholar
  57. 57.
    Natale A, Sra J, Dhala A, et al. Efficacy of different treatment strategies for neurocardiogenic syncope. Pacing Clin Electrophysiol 1995; 18: 655–62PubMedCrossRefGoogle Scholar
  58. 58.
    Sheldon R, Rose S, Flanagan P, et al. Effect of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test. Am J Cardiol 1996; 78: 536–9PubMedCrossRefGoogle Scholar
  59. 59.
    Natale A, Newby KH, Dhala A, et al. Response to beta blockers in patients with neurocardiogenic syncope: how to predict beneficial effects. J Cardiovasc Electrophysiol 1996; 7: 1154–8PubMedCrossRefGoogle Scholar
  60. 60.
    Leor J, Rotstein Z, Vered Z, et al. Absence of tachycardia during tilt test predicts failure of beta-blocker therapy in patients with neurocardiogenic syncope. Am Heart J 1994; 127: 1539–43PubMedCrossRefGoogle Scholar
  61. 61.
    Bannister R. Multiple system atrophy and pure autonomic failure. In: Low PA, editor. Clinical Autonomic Disorders. Boston (MA): Little Brown & Co., 1993: 517–25Google Scholar
  62. 62.
    Mion DJ, Rea RF, Anderson EA, et al. Effects of fludrocortisone on sympathetic nerve activity in humans. Hypertension 1994; 23: 123–30PubMedCrossRefGoogle Scholar
  63. 63.
    Grubb BP, Temesy-Armos P, Moore J, et al. The use of head-upright tilt table testing in the evaluation and management of syncope in children and adolescents. PACE 1992; 15: 742–8PubMedCrossRefGoogle Scholar
  64. 64.
    Hussain RM, McIntosh SJ, Lawson J, et al. Fludrocortisone in the treatment of hypotensive disorders in the elderly [published erratum appears in Heart 1997; 77: 294]. Heart 1996; 76: 507–9PubMedCrossRefGoogle Scholar
  65. 65.
    Strieper MJ, Campbell RM. Efficacy of alpha-adrenergic agonist therapy for prevention of pediatric neurocardiogenic syncope. J Am Coll Cardiol 1993; 22: 594–7PubMedCrossRefGoogle Scholar
  66. 66.
    Sra J, Maglio C, Biehl M, et al. Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy. J Cardiovasc Electrophysiol 1997; 8: 42–6PubMedCrossRefGoogle Scholar
  67. 67.
    Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998; 51: 120–4PubMedCrossRefGoogle Scholar
  68. 68.
    Midodrine Study Group. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, doubleblind multicenter study. JAMA 1997; 277: 1046–51CrossRefGoogle Scholar
  69. 69.
    Grubb BP, Kosinski D, Mouhaffel A, et al. The use of methyl-phenidate in the treatment of refractory neurocardiogenic syncope. Pacing Clin Electrophysiol 1996; 19: 836–40PubMedCrossRefGoogle Scholar
  70. 70.
    Susmano A, Volgman AS, Buckingham TA. Beneficial effects of dextro-amphetamine in the treatment of vasodepressor syncope. Pacing Clin Electrophysiol 1993; 16: 1235–9PubMedCrossRefGoogle Scholar
  71. 71.
    Grubb BP, Wolfe DA, Samoil D, et al. Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope. Pacing Clin Electrophysiol 1993; 16: 458–64PubMedCrossRefGoogle Scholar
  72. 72.
    Grubb BP, Samoil D, Kosinski D, et al. Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents. J Am Coll Cardiol 1994; 24: 490–4PubMedCrossRefGoogle Scholar
  73. 73.
    Lenk M, Alehan D, Ozme S, et al. The role of serotonin re-uptake inhibitors in preventing recurrent unexplained childhood syncope — a preliminary report. Eur J Pediatr 1997; 156: 747–50PubMedCrossRefGoogle Scholar
  74. 74.
    Tandan T, Giuffre M, Sheldon R. Exacerbations of neurally mediated syncope associated with sertraline. Lancet 1997; 349: 1145–6PubMedCrossRefGoogle Scholar
  75. 75.
    Grubb BP, Samoil D, Kosinski D, et al. Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension. Am J Med 1994; 97: 366–8PubMedCrossRefGoogle Scholar
  76. 76.
    van Veldhuisen DJ, Brodde OE, van Gilst WH, et al. Relation between myocardial beta-adrenoceptor density and hemodynamic and neurohumoral changes in a rat model of chronic myocardial infarction: effects of ibopamine and captopril. Cardiovasc Res 1995; 30: 386–93PubMedGoogle Scholar
  77. 77.
    Majewski H, Hedler L, Schurr C, et al. Modulation of noradrenaline release in the pithed rabbit: a role for angiotensin II. J Cardiovasc Pharmacol 1984; 6: 888–96PubMedCrossRefGoogle Scholar
  78. 78.
    Sra JS, Jazayeri MR, Avitall B, et al. Comparison of cardiac pacing with drug therapy in the treatment of neurocardiogenic (vaso-vagal) syncope with bradycardia or asystole. N Engl J Med 1993; 328: 1085–90PubMedCrossRefGoogle Scholar
  79. 79.
    Milstein S, Buetikofer J, Dunnigan A, et al. Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia. Am J Cardiol 1990; 65: 1339–44PubMedCrossRefGoogle Scholar
  80. 80.
    Vybiral T, Bryg RJ, Maddens ME, et al. Effects of transdermal scopolamine on heart rate variability in normal subjects. Am J Cardiol 1990; 65: 604–8PubMedCrossRefGoogle Scholar
  81. 81.
    Grubb BP, Temesy-Armos P, Elliott L. Utility of upright tilt-table testing in the evaluation and management of syncope of unknown origin. Am J Med 1991; 90: 6–10PubMedCrossRefGoogle Scholar
  82. 82.
    Yu JC, Sung RJ. Clinical efficacy of propantheline bromide in neurocardiogenic syncope: pharmacodynamic implications. Cardiovasc Drugs Ther 1997; 10: 687–92PubMedCrossRefGoogle Scholar
  83. 83.
    Nelson SD, Stanley M, Love CJ, et al. The autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope. Arch Intern Med 1991; 151: 2425–9PubMedCrossRefGoogle Scholar
  84. 84.
    Lee TM, Chen MF, Su SF, et al. Excessive myocardial contraction in vasovagal syncope demonstrated by echocardiography during head-up tilt test. Clin Cardiol 1996; 19: 137–40PubMedCrossRefGoogle Scholar
  85. 85.
    Anonymous. Recommendations for pacemaker prescription for symptomatic bradycardia. Report of a working party of the British Pacing and Electrophysiology Group. Br Heart J 1991; 66: 185–91CrossRefGoogle Scholar
  86. 86.
    Dreifus LS, Fisch C, Griffin JC, et al. Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Pacemaker Implantation). J Am Coll Cardiol 1991; 18: 1–13PubMedCrossRefGoogle Scholar
  87. 87.
    Sheldon R. Role of pacing in the treatment of vasovagal syncope. Am J Cardiol 1999; 84(8A): 26Q–32QPubMedCrossRefGoogle Scholar
  88. 88.
    Petersen ME, Chamberlain-Webber R, Fitzpatrick AP, et al. Permanent pacing for cardioinhibitory malignant vasovagal syndrome. Br Heart J 1994; 71: 274–81PubMedCrossRefGoogle Scholar
  89. 89.
    Ammirati F, Colivicchi F, Toscano S, et al. DDD pacing with rate drop response function versus DDI with rate hysteresis pacing for cardioinhibitory vasovagal syncope. Pacing Clin Electrophysiol 1998; 21: 2178–81PubMedCrossRefGoogle Scholar
  90. 90.
    Fitzpatrick A, Theodorakis G, Ahmed R, et al. Dual chamber pacing aborts vasovagal syncope induced by head-up 60 degrees tilt. Pacing Clin Electrophysiol 1991; 14: 13–9PubMedCrossRefGoogle Scholar
  91. 91.
    Samoil D, Grubb BP, Brewster P, et al. Comparison of single and dual chamber pacing techniques in prevention of upright tilt induced vasovagal syncope. Eur J Pacing Electrophysiol 1993; 1: 36–41Google Scholar
  92. 92.
    el-Bedawi KM, Wahbha MA, Hainsworth R. Cardiac pacing does not improve orthostatic tolerance in patients with vaso-vagal syncope. Clin Auton Res 1994; 4: 233–7PubMedCrossRefGoogle Scholar
  93. 93.
    Benditt DG, Sutton R, Gammage MD, et al. Clinical experience with Thera DR rate-drop response pacing algorithm in carotid sinus syndrome and vasovagal syncope. The International Rate-Drop Investigators Group. Pacing Clin Electrophysiol 1997; 20: 832–9PubMedCrossRefGoogle Scholar
  94. 94.
    Ector H, Reybrouck T, Heidbuchel H, et al. Tilt training: a new treatment for recurrent neurocardiogenic syncope and severe orthostatic intolerance. Pacing Clin Electrophysiol 1998; 21: 193–6PubMedCrossRefGoogle Scholar
  95. 95.
    Reybrouck T, Heidbuchel H, Van de Werf F, et al. Tilt training: a treatment for malignant and recurrent neurocardiogenic syncope. Pacing Clin Electrophysiol 2000; 23: 493–8PubMedCrossRefGoogle Scholar
  96. 96.
    Di Girolamo E, Di Iorio C, Leonzio L, et al. Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents: A controlled study. Circulation 1999; 100: 1798–801PubMedCrossRefGoogle Scholar
  97. 97.
    Brignole M, Menozzi C, Gianfranchi L, et al. A controlled trial of acute and long term medical therapy in tilt-induced neurally mediated syncope. Am J Cardiol 1992; 70: 339–42PubMedCrossRefGoogle Scholar
  98. 98.
    Moya A, Permanyer-Miralda G, Sagrista-Sauleda J, et al. Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: results of a controlled study of etilefrine versus placebo. J Am Coll Cardiol 1995; 25: 65–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Division of Cardiology, Department of Medicine, College of Physicians and SurgeonsColumbia UniversityNew YorkUSA

Personalised recommendations